WFRF:(Pfeiffer B.)
Sökning: WFRF:(Pfeiffer B.) > (2005-2009) > Short-time infusion...
- 9 av 9
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04175naa a2200505 4500 | |
| 001 | oai:DiVA.org:liu-36136 | |
| 003 | SwePub | |
| 008 | 091010s2006 | |||||||||||000 ||eng| | |
| 009 | oai:DiVA.org:uu-25381 | |
| 009 | oai:prod.swepub.kib.ki.se:1932412 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-361362 URI |
| 024 | 7 | a https://doi.org/10.1093/annonc/mdj0602 DOI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-253812 URI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:19324122 URI |
| 040 | a (SwePub)liud (SwePub)uud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Pfeiffer, P4 aut |
| 245 | 1 0 | a Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil |
| 264 | 1 | b Elsevier BV,c 2006 |
| 338 | a print2 rdacarrier | |
| 520 | a Background: The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established. Oxaliplatin induces acute, cold-induced neuropathy in most patients. The incidence is claimed to be infusion rate-dependent and therefore a 2-h infusion is recommended. Patients and methods: For practical and economic reasons, but also for patient's convenience, we performed a phase II study to examine XELOX30 (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) in patients with ACRC resistant to irinotecan. In addition the pharmacokinetics of oxaliplatin was studied. Results: From November 2002 to September 2003, 70 patients with ACRC were treated with XELOX30. Median age was 62 (range 33-74 years) years and median performance status was 1 (range 0-2). The median number of courses was four (range 1-12) and median cumulative dose of oxaliplatin was 530 (range 125-1560) mg/m2. The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2). White blood cell count (WBC) and performance status were significantly correlated to TTP. Neurotoxicity was moderate: grade 1 56%, grade 2 17% and grade 3 6%. Other grade 3 toxicities were nausea/ vomiting 9%, diarrhoea 14% and PPE 8%. The maximum blood concentration and total body clearance of oxaliplatin was higher than previously reported in studies examining 2-h infusions, but the volume of distribution and terminal half-life was in close agreement with previous results. Conclusion: XELOX30 is a very convenient second-line regimen in ACRC with an activity and safety profile similar to other oxaliplatin schedules. © 2005 European Society for Medical Oncology. | |
| 653 | a MEDICINE | |
| 653 | a MEDICIN | |
| 700 | 1 | a Sörbye, H4 aut |
| 700 | 1 | a Ehrsson, H4 aut |
| 700 | 1 | a Fokstuen, T4 aut |
| 700 | 1 | a Mortensen, JP4 aut |
| 700 | 1 | a Baltesgard, L4 aut |
| 700 | 1 | a Tveit, KM4 aut |
| 700 | 1 | a Ögreid, D4 aut |
| 700 | 1 | a Starkhammar, Hans,d 1948-u Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US4 aut0 (Swepub:liu)hanst87 |
| 700 | 1 | a Wallin, I4 aut |
| 700 | 1 | a Qvortrup, C4 aut |
| 700 | 1 | a Glimelius, Bu Karolinska Institutet,Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi4 aut |
| 710 | 2 | a Linköpings universitetb Hälsouniversitetet4 org |
| 773 | 0 | t Annals of Oncologyd : Elsevier BVg 17:2, s. 252-258q 17:2<252-258x 0923-7534x 1569-8041 |
| 856 | 4 | u https://doi.org/10.1093/annonc/mdj060 |
| 856 | 4 | u http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=16291583&dopt=Citation |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-36136 |
| 856 | 4 8 | u https://doi.org/10.1093/annonc/mdj060 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-25381 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:1932412 |
- 9 av 9
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Pfeiffer, P
- Sörbye, H
- Ehrsson, H
- Fokstuen, T
- Mortensen, JP
- Baltesgard, L
- visa fler...
- Tveit, KM
- Ögreid, D
- Starkhammar, Han ...
- Wallin, I
- Qvortrup, C
- Glimelius, B
- visa färre...
- Artiklar i publikationen
- Annals of Oncolo ...
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
